General Information of Drug (ID: DMFRW0G)

Drug Name
CEP-5214 Drug Info
Synonyms 12-(3-Hydroxypropyl)-9-(isopropoxymethyl)-6,7,12,13-tetrahydro-5H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-5-one
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Terminated [1]
Cross-matching ID
PubChem CID
10275001
TTD Drug ID
DMFRW0G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [3]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [4]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [5]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [6]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [7]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [8]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [9]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [10]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [11]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016567)
2 Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006 Aug 15;108(4):1243-50.
3 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
4 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
7 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
10 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
11 Clinical pipeline report, company report or official report of Exelixis (2011).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services